Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression

Clinical Transplantation

Volumn 15, Issue 4, 2001, Pages 276-283

  Baan, Carla C ^a,b   Van Riemsdijk van Overbeeke, Iza C ^a   Aggie Balk, H M M ^b   Pascal Vantrimpont, M A J ^c   Mol, Wendy M ^b   Knoop, Chris J ^b   Niesters, Hubert G M ^a   Lex Maat, P W M ^a   Weimar, Willem ^b  

^a Departments of Internal Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Diagnostic Institute of Molecular Biology   (Netherlands)

Author keywords

Conversion; Cyclosporin A; Heart transplantation; Tacrolimus; TGF

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; INTERLEUKIN 15; INTERLEUKIN 2; MESSENGER RNA; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG INDICATION; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; MONOCYTE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECIPIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; BLOOD PRESSURE; CHOLESTEROL; CYCLOSPORINE; CYTOKINES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TACROLIMUS;

EID: 0034908479     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2001.150410.x     Document Type: Article

References (30)

1. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report
2. CsA-induced dyslipoproteinemia is associated with selective activation of SREBP-2
3. Alterations in lipid and carbohydrate metabolism attribute to CsA A in renal transplants
4. Factors influencing the development of hypertension following cardiac transplantation
5. Renal Insufficiency after heart transplantation: A case control study
6. Hypertension in thoracic transplant recipients
7. Mechanisms of hypertension and the role of CsA
8. Chronic heart graft rejection in the clinical setting
9. An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy
10. In vivo expression of transforming growth factor-β1 in humans: Stimulation by CsA
11. In vivo hyperexpression of transforming growth factor-β1 in mice: Stimulation by CsA
12. Role of transforming growth factor-β1 in experimental chronic CsA nephropathy
13. Transforming growth factor (TGF)-β mimics and anti-TGF-β antibody abrogates the in vivo effects of CsA
14. TGF-β1 DNA polymorphisms, protein levels, and blood pressure
15. Intragraft platelet-derived growth factor-β and transforming growth factor-β1 during the development of accelerated graft vascular disease after clinical heart transplantation
16. Tacrolimus for rescue of refractory renal rejection
17. European multicenter tacrolimus (FK506) heart pilot study: One-year results - European TAC multicenter heart study group
18. A randomised, multicenter comparison of TAC and CsA immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with TAC
19. European multicenter TAC (FK506) heart pilot study: One-year results-European TAC multicenter heart study group
20. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from CsA to TAC
21. Conversion from CsA to TAC in renal allograft recipients with chronic graft nephropathy: Preliminary report
22. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group
23. Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation
24. Quantitative flow cytometry to measure the TNF-α and the IL-2 system after heart transplantation
25. Renal failure after clinical heart transplantation is associated with the TGF-β1 codon 10 gene polymorphism
26. TGF-β receptor signaling
27. Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12
28. Differential effects on CsA A and TAC on the production of TGF-beta: Implications for the development of obliterative bronchiolitis after lung transplantation
29. TGF-beta expression in renal transplant biopsies: A comparative study between CsA-A and TAC
30. CsA-associated chronic nephropathy